Viewing Study NCT00975650


Ignite Creation Date: 2025-12-24 @ 4:50 PM
Ignite Modification Date: 2025-12-28 @ 7:48 PM
Study NCT ID: NCT00975650
Status: COMPLETED
Last Update Posted: 2018-08-13
First Post: 2009-09-10
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Efficacy and Tolerability of an Intra-Nasal Testosterone Product
Sponsor: Acerus Pharmaceuticals Corporation
Organization:

Study Overview

Official Title: Efficacy and Tolerability of Nasobol®, an Intra-Nasal Testosterone Product, for Testosterone Replacement in Hypogonadal Men
Status: COMPLETED
Status Verified Date: 2018-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This clinical trial is being performed to compare the pharmacokinetic profile of testosterone after repeated intra-nasal administration of products of different strengths in subjects with hypogonadism.
Detailed Description: Primary Objective:

The primary objective of this study was to determine the efficacy of Nasobol in the treatment of hypogonadal men requiring testosterone replacement therapy. Efficacy was determined by establishing a pharmacokinetic profile for serum testosterone levels following Nasobol treatment, and comparing it to that of the active control, Androderm®.

Secondary Objective:

To establish a safety profile for Nasobol.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
TBS1-01 None None View